DE69842017D1 - Verfahren zum frühzeitigen nachweis herzerkrankungen - Google Patents

Verfahren zum frühzeitigen nachweis herzerkrankungen

Info

Publication number
DE69842017D1
DE69842017D1 DE69842017T DE69842017T DE69842017D1 DE 69842017 D1 DE69842017 D1 DE 69842017D1 DE 69842017 T DE69842017 T DE 69842017T DE 69842017 T DE69842017 T DE 69842017T DE 69842017 D1 DE69842017 D1 DE 69842017D1
Authority
DE
Germany
Prior art keywords
test sample
diseases
procedure
early detection
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69842017T
Other languages
English (en)
Inventor
Roger A Sabbadini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apollo Endosurgery Inc
Original Assignee
Apollo Endosurgery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apollo Endosurgery Inc filed Critical Apollo Endosurgery Inc
Application granted granted Critical
Publication of DE69842017D1 publication Critical patent/DE69842017D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
DE69842017T 1997-06-10 1998-05-22 Verfahren zum frühzeitigen nachweis herzerkrankungen Expired - Lifetime DE69842017D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4927497P 1997-06-10 1997-06-10
PCT/US1998/010486 WO1998057179A1 (en) 1997-06-10 1998-05-22 Methods for early detection of heart disease

Publications (1)

Publication Number Publication Date
DE69842017D1 true DE69842017D1 (de) 2011-01-05

Family

ID=21958982

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69842017T Expired - Lifetime DE69842017D1 (de) 1997-06-10 1998-05-22 Verfahren zum frühzeitigen nachweis herzerkrankungen

Country Status (8)

Country Link
US (3) US6210976B1 (de)
EP (1) EP0988552B1 (de)
JP (1) JP5264026B2 (de)
AT (1) ATE489633T1 (de)
AU (1) AU7590198A (de)
CA (1) CA2293718A1 (de)
DE (1) DE69842017D1 (de)
WO (1) WO1998057179A1 (de)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6495538B2 (en) * 1999-06-23 2002-12-17 Zinc Therapeutics, Canada Inc. Zinc ionophores as therapeutic agents
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7699790B2 (en) * 2000-12-20 2010-04-20 Ev3, Inc. Debulking catheters and methods
US20050154407A1 (en) * 2000-12-20 2005-07-14 Fox Hollow Technologies, Inc. Method of evaluating drug efficacy for treating atherosclerosis
US20100121360A9 (en) * 2000-12-20 2010-05-13 Fox Hollow Technologies, Inc Testing a patient population having a cardiovascular condition for drug efficacy
US20030096022A1 (en) * 2000-12-22 2003-05-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
JP2002243737A (ja) * 2001-02-09 2002-08-28 Azwell Inc 抗スフィンゴ脂質モノクローナル抗体
WO2002078512A2 (en) 2001-04-02 2002-10-10 Therasense, Inc. Blood glucose tracking apparatus and methods
US20040142496A1 (en) * 2001-04-23 2004-07-22 Nicholson Jeremy Kirk Methods for analysis of spectral data and their applications: atherosclerosis/coronary heart disease
US7262017B2 (en) * 2001-09-14 2007-08-28 Torrey Pines Institute For Molecular Studies Diagnostic markers for ischemia
US7202089B2 (en) * 2001-09-14 2007-04-10 Alan Kleinfeld Early diagnosis of stroke
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
GB0216191D0 (en) * 2002-07-11 2002-08-21 Univ Leicester Plasma urotensin in human heart failure
US20050014198A1 (en) * 2002-07-11 2005-01-20 Leong Ng Assays and kits for detecting and monitoring heart disease
EP2386864A1 (de) * 2002-10-09 2011-11-16 DMI Biosciences, Inc. Diagnose und Uberwachung von Ischämie
GB0224425D0 (en) * 2002-10-21 2002-11-27 Univ Leicester Method for prediction of cardiac disease
WO2004046729A2 (en) * 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
MXPA05008370A (es) * 2003-01-06 2006-03-13 Nutri Check Technologies Llc Sistema basado en las necesidades de un individuo, para el suministro de complementos.
US7074194B2 (en) * 2003-05-19 2006-07-11 Ischemia Technologies, Inc. Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin
US20040244062A1 (en) * 2003-06-02 2004-12-02 Crittenden Jill R. Use of protein inhibitors as antithrombotic agents
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
EP1522857A1 (de) * 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
DE10351238A1 (de) * 2003-11-03 2005-06-02 Roche Diagnostics Gmbh Diagnosestellung von akuten myokardialen, ischämischen Erkrankungen durch Kombination von Markern
US20050100964A1 (en) * 2003-11-11 2005-05-12 George Jackowski Diagnostic methods for congestive heart failure
US7608458B2 (en) * 2004-02-05 2009-10-27 Medtronic, Inc. Identifying patients at risk for life threatening arrhythmias
CA2554836A1 (en) * 2004-02-05 2005-08-25 Medtronic, Inc. Methods and apparatus for identifying patients at risk for life threatening arrhythmias
WO2005089103A2 (en) 2004-02-17 2005-09-29 Therasense, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
WO2005093103A2 (en) * 2004-03-22 2005-10-06 Ffa Sciences, Llp Development and use of fluorescent probes of unbound analytes
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20050287574A1 (en) * 2004-06-23 2005-12-29 Medtronic, Inc. Genetic diagnostic method for SCD risk stratification
US8027791B2 (en) * 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
US8335652B2 (en) * 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
US7462268B2 (en) * 2004-08-20 2008-12-09 Allan Mishra Particle/cell separation device and compositions
US20060088860A1 (en) * 2004-09-13 2006-04-27 Lipomics Technologies, Inc. Metabolite markers for weight management
WO2006094185A2 (en) * 2005-03-03 2006-09-08 Dmi Biosciences Inc. Quantification of proteins
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
US20060246574A1 (en) * 2005-04-29 2006-11-02 Sarah Rosenstein Dispenser for making a lateral flow device
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US20060246599A1 (en) * 2005-04-29 2006-11-02 Sarah Rosenstein Lateral flow device
CA2605084C (en) * 2005-04-29 2013-11-05 Norman R. Byrne Center connect single-sided junction block
US20060257938A1 (en) * 2005-05-10 2006-11-16 Kleinfeld Alan M Method of screening for drugs that block ligand binding to a lipid binding protein
JP4850001B2 (ja) * 2005-09-05 2012-01-11 プリマハム株式会社 新規ストレスバイオマーカー及びその用途
US20070065954A1 (en) * 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
US20070077200A1 (en) * 2005-09-30 2007-04-05 Baker Clark R Method and system for controlled maintenance of hypoxia for therapeutic or diagnostic purposes
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US7878644B2 (en) 2005-11-16 2011-02-01 Gerber Scientific International, Inc. Light cure of cationic ink on acidic substrates
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
EP3255432B1 (de) * 2006-04-24 2019-01-23 Critical Care Diagnostics, Inc. Vorhersage von letalität und detektion von schweren erkrankungen
ATE517341T1 (de) * 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
SI2482078T1 (sl) * 2006-05-01 2016-05-31 Critical Care Diagnostics, Inc. Diagnosticiranje kardiovaskularne bolezni
ES2542343T3 (es) * 2006-05-02 2015-08-04 Critical Care Diagnostics, Inc. Diagnóstico diferencial entre enfermedad pulmonar y cardiovascular
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US20080138334A1 (en) * 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US20080071158A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
US9164109B2 (en) 2006-10-27 2015-10-20 Alan Kleinfeld Use of probes for unbound metabolites
MX2009004532A (es) * 2006-10-27 2009-09-04 Lpath Inc Composiciones y metodos para unir esfingosina-1-fosfato.
WO2008055072A2 (en) * 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
JP5105583B2 (ja) * 2007-03-14 2012-12-26 国立大学法人信州大学 心血管系疾患既往区別方法
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
EP2153236A1 (de) * 2007-06-07 2010-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur beurteilung des risikos einer herz-kreislauf-erkrankung und zur diagnose von dyslipidämie
US20100285446A1 (en) * 2007-07-20 2010-11-11 Akos Vertes Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
DE102007042986A1 (de) * 2007-09-10 2009-04-23 Siemens Ag Medizinisches Gerät und Verfahren zum Betreiben eines medizinischen Geräts
EP2205978B1 (de) * 2007-09-17 2011-11-23 BG Medicine, Inc. Beurteilung des risikos von kongestiver herzinsuffizienz bei patienten, die mit einem peroxisom-proliferator-aktivator-rezeptor-gamma-agonisten oder einem thiazolidindion behandelt werden oder möglicherweise damit behandelt werden sollen
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP2222877A4 (de) * 2007-11-14 2011-10-12 Medtronic Inc Genetische marker für die scd- oder sca-therapieauswahl
US20110143956A1 (en) * 2007-11-14 2011-06-16 Medtronic, Inc. Diagnostic Kits and Methods for SCD or SCA Therapy Selection
WO2009070457A1 (en) * 2007-11-30 2009-06-04 Waters Technologies Corporation Determining the presence or absence of mineralocorticoids in samples
WO2009129454A2 (en) 2008-04-18 2009-10-22 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
US7811749B2 (en) * 2008-04-21 2010-10-12 Abbott Laboratories Measuring free choline to determine suitability of erythrocytes for transfusion
WO2010042658A1 (en) * 2008-10-07 2010-04-15 Bioparadox, Llc Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
EP2337617A4 (de) * 2008-10-09 2013-06-12 Bioparadox Llc Plättchenreiche plasmaformulierungen für herzbehandlungen
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
AU2009340423B2 (en) * 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US20110076697A1 (en) * 2009-04-28 2011-03-31 Innovative Laboratory Technologies, Inc. Lateral-flow immuno-chromatographic assay devices
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
EP2430184A2 (de) * 2009-05-12 2012-03-21 Medtronic, Inc. Sca-risikostratifizierung durch vorhersage des ansprechens von patienten auf antiarrhythmika
WO2010138856A1 (en) 2009-05-29 2010-12-02 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
CN102576028A (zh) 2009-08-25 2012-07-11 保函医药公司 半乳凝集素-3和心脏再同步疗法
EP2473099A4 (de) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc Analytüberwachungssystem und -verfahren zur leistungs- und rauschverwaltung
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
WO2011041469A1 (en) 2009-09-29 2011-04-07 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
WO2011089146A1 (en) 2010-01-20 2011-07-28 Universität Zürich Method for assaying diseases characterised by dyslipidemia
CA3012137A1 (en) * 2010-01-29 2011-08-04 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
ES2455124T5 (es) 2010-05-05 2018-05-08 Zora Biosciences Oy Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca
US9201080B2 (en) 2010-06-20 2015-12-01 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients
EP2588111A1 (de) 2010-07-02 2013-05-08 BG Medicine, Inc. Mittels galectin-3-messung überwachte statintherapie
MX2013008839A (es) 2011-01-31 2013-11-04 Bg Medicine Inc Uso de galectina-3 para detectar y diagnosticar insuficiencia cardiaca posterior al sindrome coronario agudo.
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
WO2013085572A2 (en) 2011-07-14 2013-06-13 The George Washington University Plume collimation for laser ablation electrospray ionization mass spectrometry
EP3190418B1 (de) * 2011-07-28 2019-05-01 metanomics GmbH Verwendung von sm_sphingomyelin (d18:1, c16:0) als marker für herzversagen
WO2013070794A2 (en) 2011-11-07 2013-05-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods
EP2592422A1 (de) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomik-Biomarker zur Prognose von kardiosvaskulären Ergebnissen bei Patienten mit Erkrankung der Herzkranzgefäße unter Statinbehandlung
EP2592423A1 (de) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomik-Biomarker zur Prognose von kardiosvaskulären Ergebnissen bei Patienten mit Erkrankung der Herzkranzgefäße ohne Statinbehandlung
JP2015505368A (ja) 2012-01-06 2015-02-19 ビージー メディシン， インコーポレイテッド 妊娠高血圧腎症および関連状態のリスク評価および検出のためのガレクチン−３の使用
JP6450679B2 (ja) 2012-08-21 2019-01-09 クリティカル ケア ダイアグノスティクス インコーポレイテッド マルチマーカーリスク層別化
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation
WO2015095882A1 (en) * 2013-12-20 2015-06-25 The Regents Of The University Of California Biomimetic virus-based colorimetric sensors
KR101799985B1 (ko) 2016-09-02 2017-11-21 아주대학교산학협력단 S1p 및 스핑고신을 이용한 중증천식의 진단방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5510590A (en) * 1978-05-04 1980-01-25 Wellcome Found Enzyme immunity quantity analysis
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
CA2027434C (en) 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5710008B1 (en) 1990-10-12 1999-09-07 Spectral Diagnostics Inc Method and device for diagnosing and distinguishing chest pain in early onset thereof
US5604105B1 (en) * 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
RU2003979C1 (ru) * 1991-06-28 1993-11-30 Московский областной научно-исследовательский клинический институт им.М.Ф.Владимирского Способ прогнозировани течени послеоперационного периода у больных врожденными пороками сердца

Also Published As

Publication number Publication date
JP5264026B2 (ja) 2013-08-14
EP0988552B1 (de) 2010-11-24
US6534323B1 (en) 2003-03-18
CA2293718A1 (en) 1998-12-17
ATE489633T1 (de) 2010-12-15
JP2002504999A (ja) 2002-02-12
US6534322B1 (en) 2003-03-18
EP0988552A1 (de) 2000-03-29
US6210976B1 (en) 2001-04-03
AU7590198A (en) 1998-12-30
WO1998057179A1 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
DE69842017D1 (de) Verfahren zum frühzeitigen nachweis herzerkrankungen
ATE256869T1 (de) Probendetektion zum initiieren der zeitmessung eines elektrochemischen tests
ATE278803T1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
ATE408829T1 (de) Verfahren und assaykits zum nachweis mononuklearer zellphänotypen
ATE408709T1 (de) Homogenes verfahren zum testen von duplex- oder triplex-hybridisierungen mittels durchführung von mehreren messungen unter verschiedenen bedingungen
MX9707889A (es) Metodo y dispositivo para diagnosticar y distinguir dolor de pecho en inicio temprano del mismo.
ATE509275T1 (de) Schnelltest für glykiertes albumin
ATE361470T1 (de) Verfahren zur diagnose von immunologischer lebensmittelsensitivität
ATE279531T1 (de) Test zum nachweis der aktivität von phospho-n- acetylmuramyl-pentapeptid-translokase
ATE316653T1 (de) Test zum direkten nachweis eines inflammatorischen anzeiger in einer körperflüssigkeitsprobe
BR0107984A (pt) Método e dispositivo para efetuar medição de tira de teste
DE60143355D1 (de) Verbessertes einfangen und detektion von zielnukleinsäuren in verfahren mit teststreifen
ATE421595T1 (de) Zusammensetzungen und verfahren zum nachweis und zur quantifizierung von cox-2-aktivität und 2- arachidonylglycerin-metaboliten
DE59905904D1 (de) Vorrichtung zum Messen von Eigenschaften eines längsbewegten Prüfguts
CA2586654A1 (en) Use of asc as a marker for colorectal cancer
DE60112949D1 (de) Verfahren zum nachweis eines lipoprotein-akutphaseprotein-komplexes
WO2003076896A3 (en) Use of biomarkers to detect breast cancer
ATE103990T1 (de) Verfahren zur diagnose der periodontalen krankheit mittels nachweis von alaninaminotransferase.
HUP0100948A2 (hu) Antitest kompeticiós teszt (AKT) P-glikoprotein és egyéb sejtfelszíni receptorok, pumpák és fehérjék konformáció-változásainak kvalitatív, illetve konformáció-függő kvantitatív kimutatására és annak alkalmazásai
ATE437368T1 (de) Verfahren zum prüfen von mit wt1-verbundenen krankheiten
DE69731194D1 (de) Analyse zum nachweis von degenerativen hirnerkrankungen
DE60225168D1 (de) Verfahren zur auswahl bioaktiver wirkstoffe durch lumineszenzkopplung und lebendes zellensystem dafür
DE69929817D1 (de) Verfahren zur aktivitätsbestimmung einer substanz mittels eines funktionellen in vitro tests
NO20016080L (no) Analyse
ATE432364T1 (de) Sonden zum nachweis von tumorzellen